Corcept Therapeutics (CORT) Common Equity (2010 - 2026)

Corcept Therapeutics has disclosed Common Equity across 17 years of filings, most recently posting $638.0 million for Q1 2026.

• Common Equity for Q1 2026 came in at $638.0 million, down 6.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $638.0 million (down 6.63% YoY), and the FY2025 annual result was $647.8 million, down 4.68% from the prior year.
• Common Equity came in at $638.0 million for Q1 2026 at Corcept Therapeutics, down from $647.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $683.3 million in Q1 2025 to a low of $407.8 million in Q1 2022.
• The 5-year median for Common Equity is $547.9 million (2024), against an average of $555.5 million.
• Across the five-year window, Common Equity retreated 20.16% in 2022 and jumped 41.42% in 2024, its largest moves.
• Corcept Therapeutics' Common Equity stood at $501.8 million in 2022, then rose by 0.97% to $506.7 million in 2023, then surged by 34.12% to $679.6 million in 2024, then dropped by 4.68% to $647.8 million in 2025, then declined by 1.52% to $638.0 million in 2026.
• The last three Common Equity figures came in at $638.0 million (Q1 2026), $647.8 million (Q4 2025), and $631.9 million (Q3 2025), per Business Quant data.